Walleye Capital’s Evolent Health EVH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$310K Sell
135,948
-2,784
-2% -$8.83K ﹤0.01% 3040
2025
Q4
$555K Sell
138,732
-515,729
-79% -$2.87M ﹤0.01% 2895
2025
Q3
$5.54M Buy
654,461
+6,700
+1% +$65K 0.02% 871
2025
Q2
$7.29M Buy
647,761
+595,458
+1,138% +$5.47M 0.03% 660
2025
Q1
$495K Buy
52,303
+48,689
+1,347% +$492K ﹤0.01% 2570
2024
Q4
$40.7K Buy
3,614
+678
+23% +$11.9K ﹤0.01% 4406
2024
Q3
$83K Sell
2,936
-5,512
-65% -$142K ﹤0.01% 4472
2024
Q2
$162K Buy
+8,448
New +$216K ﹤0.01% 4448
2021
Q4
Sell
-27,662
Closed -$858 2163
2021
Q3
$858 Buy
+27,662
New +$664K 0.02% 535
2019
Q4
Sell
-49,368
Closed -$355K 1921
2019
Q3
$355K Buy
49,368
+20,597
+72% +$148K 0.02% 900
2019
Q2
$229K Buy
+28,771
New +$341K 0.03% 891

Other funds holding EVH

Walleye Capital's EVH Position: Q1 2026 in Review

Walleye Capital reduced its Evolent Health (EVH) stake by 2% in Q1 2026, selling an estimated $8.83K and leaving 135,948 shares worth $310K. The position accounts for ﹤0.01% of the portfolio, ranked #3040.

Walleye Capital first reported a position in EVH in Q2 2019 and has held it in 11 quarters since. The position peaked at $7.29M in Q2 2025. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

  • Walleye Capital held 135,948 shares of Evolent Health worth $310K as of Q1 2026.
  • Walleye Capital sold 2,784 Evolent Health shares in Q1 2026, an estimated $8.83K.
  • Evolent Health made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3040 holding.
  • Walleye Capital first reported a position in Evolent Health in Q2 2019 and has held it in 11 quarters since.
  • Walleye Capital's Evolent Health position peaked at $7.29M in Q2 2025.
  • 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.